Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | PLK1 | P53350 | 1/20 | 0.61 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30071626 | 1.00 | MMP3 (0.62) | MMP3HDAC8PLK1NR4A1NR4A2 | |
| Guanidine SCHEMBL27689978 | 0.98 | MMP3 (0.61) | MMP3HDAC8PLK1NR4A1NR4A2 | |
| Hydrochloric Acid SCHEMBL7110749 | 0.98 | MMP3 (0.61) | MMP3HDAC8PLK1NR4A1NR4A2 | |
| SCHEMBL1794660 | 0.87 | MMP3 (0.65) | MMP3HDAC8PLK1NR4A1NR4A2 | |
| Heptane SCHEMBL27371329 | 0.87 | PLK1 (0.51) | MMP3HDAC8PLK1SCN5ASCN2A | |
| SCHEMBL1605906 | 0.87 | HDAC8 (0.74) | MMP3HDAC8PLK1NR4A1NR4A2 | |
| SCHEMBL27689914 | 0.86 | SCN5A (0.54) | MMP3HDAC8PLK1NR4A1NR4A2 | |
| SCHEMBL5427460 | 0.85 | MMP3 (0.67) | MMP3HDAC8PLK1NR4A1NR4A2 | |
| SCHEMBL3070336 | 0.85 | ALDH1A1 (0.42) | MMP3HDAC8PLK1ALDH1A1KDM4E | |
| SCHEMBL15121479 | 0.84 | PLAU (0.52) | MMP3HDAC8PLK1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617709-B1 | Guanidine derivatives as antiviral agents | BIOTRON LTD (AU) | 2022-11-16 | — | — | EP | claimed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | claimed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | claimed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | claimed |
| EP-2617709-A1 | Guanidine derivatives as antiviral agents | Biotron Limited (AU) | 2013-07-24 | — | — | EP | claimed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | claimed |
| CN-101111475-B | Antiviral compounds and methods | BIOTRON LTD | 2012-09-05 | — | — | CN | claimed |
| EP-0937464-B1 | Combined pharmaceutical preparation containing inhibitors of the sodium hydrogen exchange and a medicament for the treatment of cardiovascular diseases | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-07-11 | — | — | EP | claimed |
| CN-101111475-A | Antiviral compounds and methods | BIOTRON LTD (AU) | 2008-01-23 | — | — | CN | claimed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | claimed |
| US-6420430-B1 | USE OF BENZOYLGUANIDINE DERIVATIVES TO PREVENT AGING DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-16 | — | — | US | claimed |
| EP-1140056-A2 | THE UTILISATION OF INHIBITORS OF THE SODIUM HYDROGEN EXCHANGER FOR PRODUCING A MEDICAMENT FOR PREVENTING ORGAN DYSFUNCTIONS AND DISEASES RELATED TO A PARTICULAR AGE AND FOR PROLONGING LIFE | Aventis Pharma Deutschland GmbH (DE) | 2001-10-10 | — | — | EP | claimed |
| EP-0810205-B1 | Substituted 1-naphtoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicaments containing them | HOECHST AG (DE) | 2001-03-28 | — | — | EP | claimed |
| WO-2000038661-A2 | THE UTILISATION OF INHIBITORS OF THE SODIUM HYDROGEN EXCHANGER FOR PRODUCING A MEDICAMENT FOR PREVENTING ORGAN DYSFUNCTIONS AND DISEASES RELATED TO A PARTICULAR AGE AND FOR PROLONGING LIFE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-07-06 | — | — | WO | claimed |
| EP-0937464-A2 | Combined pharmaceutical preparation containing inhibitors of the sodium hydrogen exchange and a medicament for the treatment of cardiovascular diseases | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-08-25 | — | — | EP | claimed |
| EP-0916337-A2 | Use of inhibitors of the sodium-hydrogen exchange in the manufacture of amedicament for reducing unwanted effects of compounds on the heart. | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-05-19 | — | — | EP | claimed |
| EP-0909559-A2 | Use of inhibitors of the sodium hydrogen exchange in the manufacture of a medicament for treatment or prophylaxis of diseases of the central nervous system | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-21 | — | — | EP | claimed |
| EP-0901788-A2 | Use of inhibitors of the sodium hydrogen exchange in the manufacture of a medicament | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-03-17 | — | — | EP | claimed |
| CN-1209995-A | Use of sodium-hydrogen exchanger inhibitors for the production of a medicament for reducing the adverse effects of substances on the heart | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-03-10 | — | — | CN | claimed |
| EP-0810205-A1 | Substituted 1-naphtoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472332-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | MMP3 787/4885HDAC8 278/4885PLK1 542/4885 |
| US-20070099968-A1 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | MMP3 711/4885HDAC8 284/4885PLK1 594/4885 |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | MMP3 787/4885HDAC8 278/4885PLK1 542/4885 |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | MMP3 644/4885HDAC8 222/4885PLK1 511/4885 |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | MMP3 644/4885HDAC8 222/4885PLK1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.